Swiss National Bank Rubius Therapeutics, Inc. Transaction History

Swiss National Bank

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$0.79 - $5.98 $75,524 - $571,688	-95,600 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$4.25 - $10.4 $28,475 - $69,680	6,700 Added 7.54%	95,600 $527,000
Q3 2021 Nov 08, 2021	BUY	$17.6 - $25.91 $147,840 - $217,644	8,400 Added 10.43%	88,900 $1.59 Million
Q2 2021 Aug 06, 2021	SELL	$22.26 - $28.43 $53,424 - $68,232	-2,400 Reduced 2.9%	80,500 $1.97 Million
Q1 2021 May 07, 2021	BUY	$8.02 - $32.01 $80,200 - $320,100	10,000 Added 13.72%	82,900 $2.2 Million
Q2 2020 Aug 05, 2020	BUY	$4.01 - $6.88 $48,120 - $82,560	12,000 Added 19.7%	72,900 $436,000
Q4 2019 Feb 06, 2020	BUY	$7.23 - $14.12 $10,845 - $21,180	1,500 Added 2.53%	60,900 $579,000
Q2 2019 Aug 02, 2019	BUY	$13.5 - $19.94 $801,900 - $1.18 Million	59,400 New	59,400 $934,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.